258 related articles for article (PubMed ID: 9731501)
1. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Zuckier LS; Chang CJ; Scharff MD; Morrison SL
Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
[TBL] [Abstract][Full Text] [Related]
2. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
Tao MH; Morrison SL
J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
[TBL] [Abstract][Full Text] [Related]
3. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
4. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
5. Genetic engineering of bovine Ig. Construction and characterization of hapten-binding bovine/murine chimeric IgE, IgA, IgG1, IgG2, and IgG3 molecules.
Knight KL; Suter M; Becker RS
J Immunol; 1988 May; 140(10):3654-9. PubMed ID: 3361125
[TBL] [Abstract][Full Text] [Related]
6. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects.
Papadea C; Check IJ
Crit Rev Clin Lab Sci; 1989; 27(1):27-58. PubMed ID: 2647414
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of IgM rheumatoid factor binding to chimeric IgG.
Artandi SE; Canfield SM; Tao MH; Calame KL; Morrison SL; Bonagura VR
J Immunol; 1991 Jan; 146(2):603-10. PubMed ID: 1702808
[TBL] [Abstract][Full Text] [Related]
8. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent.
Reist CJ; Bigner DD; Zalutsky MR
Clin Cancer Res; 1998 Oct; 4(10):2495-502. PubMed ID: 9796983
[TBL] [Abstract][Full Text] [Related]
9. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein.
Cox GN; Smith DJ; Carlson SJ; Bendele AM; Chlipala EA; Doherty DH
Exp Hematol; 2004 May; 32(5):441-9. PubMed ID: 15145212
[TBL] [Abstract][Full Text] [Related]
10. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
11. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions.
Heinrich G; Gram H; Kocher HP; Schreier MH; Ryffel B; Akbar A; Amlot PL; Janossy G
J Immunol; 1989 Dec; 143(11):3589-97. PubMed ID: 2479683
[TBL] [Abstract][Full Text] [Related]
13. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
14. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
15. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies.
Ichikawa K; Tsutsumi A; Atsumi T; Matsuura E; Kobayashi S; Hughes GR; Khamashta MA; Koike T
Arthritis Rheum; 1999 Nov; 42(11):2461-70. PubMed ID: 10555042
[TBL] [Abstract][Full Text] [Related]
16. Influence of the isotype of the light chain on the properties of IgG.
Montaño RF; Morrison SL
J Immunol; 2002 Jan; 168(1):224-31. PubMed ID: 11751966
[TBL] [Abstract][Full Text] [Related]
17. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin.
He XY; Xu Z; Melrose J; Mullowney A; Vasquez M; Queen C; Vexler V; Klingbeil C; Co MS; Berg EL
J Immunol; 1998 Jan; 160(2):1029-35. PubMed ID: 9551944
[TBL] [Abstract][Full Text] [Related]
18. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
19. Baboon immunoglobulin constant region heavy chains: identification of four IGHG genes.
Attanasio R; Jayashankar L; Engleman CN; Scinicariello F
Immunogenetics; 2002 Nov; 54(8):556-61. PubMed ID: 12439618
[TBL] [Abstract][Full Text] [Related]
20. Immunochemical study of a human myeloma IgG1 half molecule.
Seligmann M; Mihaesco E; Chevalier A; Miglierina R
Ann Immunol (Paris); 1978; 129 C(6):855-70. PubMed ID: 85430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
